±Û·Î¹úÁ¦¾à ÀÓ»óMA/ MSL/ Sr.RA/ Sr.PMS/ QA/ Market Access

¸ðÁýºÎ¹® ¹× ÀÚ°Ý¿ä°Ç

¸ðÁýºÎ¹® ´ã´ç¾÷¹« ÀÚ°Ý¿ä°Ç Àοø
ÀÓ»ó

[´ã´ç¾÷¹«]

1. ÀÓ»óMA( Clinical Medical Affairs Manager)

*ÁÖ¿ä¾÷¹«:
´ç´¢º´, ºñ¸¸, ½ÉÇ÷°üÁúȯ, °£Áúȯ, ½ÅÀåÁúȯ ¹× ½Å±Ô Ä¡·á¿µ¿ª¿¡¼­ ¼öÇàµÇ´Â
ÀÓ»ó½ÃÇèÀÌ ¼º°øÀûÀ¸·Î ÁøÇàµÉ ¼ö ÀÖµµ·Ï ÀÇÇÐÀû¡¤°úÇÐÀû Áö¿øÀ» ´ã´ç.
ÀÓ»ó½ÃÇè Àü·« ¼ö¸³/ ¿¬±¸ÀÚ¿ÍÀÇ Scientific Partnership ±¸Ãà/ ¿¬±¸ÀÚ ±³À°/
Investigator Engagement/ Trial Scientific Leadership±îÁö ´ã´çÇÏ´Â
ÀÓ»ó°³¹ß Áß½ÉÀÇ Medical AffairsÆ÷Áö¼Ç

*ÀÚ°Ý:
- MD, PhD, PharmD, ¾à»ç Áß Çϳª¿¡ ÇØ´ç µÇ½Ã´Â ºÐ
- ÃÖ¼Ò 5³â ÀÌ»ó Medical Affairs °æ·Â Çʼö(±Û·Î¹úÁ¦¾à °æÇè ¼±È£)
- ³í¹® ÀúÀÚ °æÇè ¹× Á¦¾àȸ»ç Clinical Development °æÇè
- Scientific Communication ´É·Â ¹× Presentation Skill
- Cross-functional Collaboration ´É·Â

2. (Sr.) MSL Specialist (TO 2¸í)

*ÁÖ¿ä¾÷¹«:
- KOL°úÀÇ Àü·«Àû, ÀÇÇÐÀû Communication
- Investigator Sponsored Study (IIS) °ü¸®
- KOL °ü¸® ¹× Medical Activity ¼öÇà
- Medical Insight »ý¼º ¹× ¿µ¾÷ ¸¶ÄÉÆÃ ±³À°
- Business Ethics À̽´ °ü¸® ¹× º¸°í

*ÀÚ°Ý:
- MSL, Medical Affairs °æ·Â 4 ³â ÀÌ»ó
- ±Û·Î¹úÁ¦¾à °æ·Â ¹× ¾à»ç ¼±È£
- ±¹³» ÀÇ·áÁø ³×Æ®¿öÅ© º¸À¯ÀÚ
- Good command of English

3. Sr.RA specialist (TO: 2¸í)
- ±Û·Î¹úÁ¦¾à RA°æ·Â 5³â ~ 10³â Çʼö
- ½Å¾à µî·Ï ¹× GMP inspection °æÇè Çʼö
- ±ÔÁ¦ÀÎÇã°¡ Àü·«, ÀÌÇØ°ü°èÀÚ ¼ÒÅë, ¸®½ºÅ©°ü¸® °æÇèÀÚ ¼±È£

4. (Sr.) PMS Specialist
- PMS/PASS ÇÁ·ÎÁ§Æ®¸¦ ÇÁ·ÎÅäÄÝ ¼³°èºÎÅÍ ÃÖÁ¾ º¸°í±îÁö End-to-End·Î °ü¸®
- ȸ»ç ³»ºÎ ±ÔÁ¤, ICH-GCP/GPP, Çï½ÌŰ ¼±¾ð, Çѱ¹ °ü·Ã ¹ý±Ô Áؼö °ü¸®
- ÇÁ·ÎÁ§Æ® ¿¹»ê °ü¸® ¹× TMF(Trial Master File) ¹× ÀÓ»ó ½Ã½ºÅÛ ¹®¼­ °ü¸®
- ÀûÀýÇÑ ¿¬±¸±â°ü(site) ¼±Á¤ ¹× Æò°¡ (¶óÀÎ ¸Å´ÏÀú ¹× ÀÌÇØ°ü°èÀÚ Çù¾÷)
- º¸°Ç´ç±¹ ¹× IRB/À±¸®À§¿øÈ¸¿ÍÀÇ Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× ¹®¼­ Á¦Ãâ
- º¥´õ ¹× CRO °ü¸® ¹× ¿ÜºÎ Çù·Â ǰÁú °¨µ¶
- ¸ðµç ÀÏÁ¤°ú »êÃâ¹° Áؼö º¸Àå
- PMS/PASS °æ·Â 7³â ~ 10³â (Çʼö ÃÖ¼Ò 5³â, ¿ÜÀÚ»ç °æ·Â Çʼö)

5. QA Manager
- QMS ¿î¿µÀ¯Áö ¹× Çѱ¹ ¹ýÀÎÀÇ QMR¿ªÇÒ ¼öÇà
- ÀÏŻó¸®, Potential Recall, Á¦Ç° ÃâÇÏ ½ÂÀÎ µî ÇÙ½É QA ÇÁ·Î¼¼½º °ü¸®
- ³»ºÎ ¿î¿µ ¹× ¿ÜºÎ Çù·Â»ç¸¦ ´ë»óÀ¸·Î Lead Auditor¿ªÇÒ ¼öÇà
- QAÆÀ¿øÀÇ ¸®µù, À°¼º ¹× ÄÚĪ, QAÆÀ ¿¹»ê °ü¸® ¾÷¹«
- ±Û·Î¹úÁ¦¾à Æ÷ÇÔ Quality °ü·Ã °æ·Â 10³â~20³â
- 2³â ÀÌ»óÀÇ ÆÀ¿ø °ü¸® °æÇè(ÆÀ ¸®µù, À°¼º, ÄÚĪ ¿ª·® Çʼö)
- Çѱ¹ ¾à»ç ¸éÇã Çʼö ¹× Business¿µ¾î Ä¿¹Â´ÏÄÉÀÌ¼Ç ´É·Â

6. Market Access (Sr.) Specialist
- ±¹³» ½ÃÀå Á¢±Ù Àü·« ¹× ½ÇÇà °èȹ ¼ö¸³
- ¿ÜºÎ º¥´õ¿Í Çù¾÷ÇÏ¿© ±¹³» ¸ÂÃãÇü ¾à¹°°æÁ¦¼º ¿¬±¸ ¼öÇà
- ½Å±Ô ´ã´ç Á¦Ç°¿¡ ´ëÇÑ ¾à°¡ ¹× ±Þ¿© Àü·«/°èȹ ¼ö¸³
- ½ÃÀå Á¢±Ù ȯ°æ º¯È­ ¸ð´ÏÅ͸µ ¹× °ü·Ã ºÎ¼­¿Í Çù¾÷ÇÏ¿© ÃÖÀûÀÇ ¾à°¡ À¯Áö
- HIRA, NHIS, MoHW¿ÍÀÇ °¡Ä¡ Ä¿¹Â´ÏÄÉÀÌ¼Ç ¼öÇà
- Market Access ¶Ç´Â HTA ºÐ¾ß¿¡¼­ ÃÖ¼Ò 2³â ÀÌ»ó °æÇèÀÚ
- HTA Æò°¡¸¦ ÁÖµµÇÒ ¼ö ÀÖ´Â ¼öÁØÀÇ ¾à¹°°æÁ¦¼º ºÐ¼® Áö½Ä ¹× °æÇè º¸À¯
- Ç×¾ÏÁ¦ÀÇ ½Å¾à µîÀç ¶Ç´Â ±Þ¿© È®´ë¿¡ ´ëÇÑ °æÁ¦¼ºÆò°¡ °æÇèÀÚ ¼±È£

7. Market Access Lead
- Market Access ½ÃÀåȯ°æ ºÐ¼® ¹× Àü·« ¼ö¸³
- Health Economics ¹× Value Communication
- Value Dossier ÀÛ¼º ¹× Pricing Strategy
- ±Û·Î¹ú Á¦¾àȸ»ç ¶Ç´Â ´ëÇü Á¦¾à»çÀÇ MA °æ·Â 10³â ÀÌ»ó
- ¾à°¡(Pricing) ¹× ±Þ¿©µîÀç(Reimbursement) ½Ç¹« °æÇè
- HIRA¡¤±¹¹Î°Ç°­º¸Çè°ø´Ü(NHIS) Çù»ó °æÇè
- HTA ¹× ¾à¹°°æÁ¦¼º ÇÁ·ÎÁ§Æ® ¼öÇà °æÇè
- Value Dossier ÀÛ¼º ¹× Value Communication °æÇè
- ±Û·Î¹ú º»»ç¿ÍÀÇ Çù¾÷ ¹× ¿µ¾î Ä¿¹Â´ÏÄÉÀÌ¼Ç ´É·Â


JNÆÄÆ®³ÊÁîÄÚ¸®¾Æ

ÇѼ®Áß_ÀÌ»ç / ***-****-****
******@*******.***

[ÀÚ°Ý¿ä°Ç]

°æ·Â: °æ·Â 4~18³â
ÇзÂ: ´ëÁ¹ ÀÌ»ó
Á÷¹«±â¼ú: Medical Affairs


±Ù¹«Á¶°Ç

  • °í¿ëÇüÅÂ: Á¤±ÔÁ÷
  • ±Þ¿©Á¶°Ç: ȸ»ç³»±Ô

ÀüÇü´Ü°è ¹× Á¦Ãâ¼­·ù

  • ÀüÇü´Ü°è: ¼­·ùÀüÇü > ¸éÁ¢ÁøÇà > ÃÖÁ¾½É»ç > ÃÖÁ¾ÇÕ°Ý
  • Ãß°¡ Á¦Ãâ¼­·ù
    À̷¼­, ÀÚ±â¼Ò°³¼­

Á¢¼ö¹æ¹ý

  • Á¢¼ö¹æ¹ý: ÀÎÅ©·çÆ® Á¢¼ö, À̸ÞÀÏ
  • Á¢¼ö¾ç½Ä: ÀÎÅ©·çÆ® À̷¼­

±âŸ À¯ÀÇ»çÇ×

  • ÀÔ»çÁö¿ø¼­ ¹× Á¦Ãâ¼­·ù¿¡ ÇãÀ§»ç½ÇÀÌ ÀÖÀ» °æ¿ì ä¿ëÀÌ Ãë¼ÒµÉ ¼ö ÀÖ½À´Ï´Ù.

00